A shot of 1.2 million anti-cancer drug is CAR-T therapy (Chimeric Antigen Receptor T Cell Immunotherapy), which is a kind of immunotherapy. Simply put, T-cells are extracted from the recipient’s blood (to help the body produce immunity), modified so that the modified T-cells can effectively kill cancer cells, and reintroduced into the body for the purpose of treating cancer. CAR-T treatment is not an injection that requires $1.2 million, but the cost of the entire process from the design of the treatment plan to the completion of the final treatment, which requires a multi-person professional medical team to go through the pre-treatment evaluation, isolation of T-cells, remodeling of the T-cells, expansion of the CAR-T cells, re-infusion into the body, post-treatment evaluation, monitoring, and finally the completion of the treatment. CAR-T therapy is generally considered when conventional chemotherapy, radiotherapy, targeted therapy and other treatments are ineffective. Currently CAR-T therapy has significant limitations and is only applicable to hematologic-related tumors such as leukemia, lymphoma, and multiple myeloma. It is less effective for other solid tumors and requires further research.